Clinical trial NCT03342196: Thiotepa Plus Fludarabine+ Melphalan as the Preparative Regime for Alternative Donor Transplantation
Official title: A Phase II Study of Thiotepa Added to Fludarabine and Melphalan as the Preparative Regime for Alternative Donor Transplantation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Leukemia
Keywords: Thiotepa
Fludarabine
Melphalan
Lead sponsor: Case Comprehensive Cancer Center
Sponsor class: OTHER
First posted: 2017-11-14
Enrollment: 39
Sex: ALL
Minimum age (years): 1
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: In the United States, thiotepa has been utilized in reduced intensity conditioning regimens for alternative donor courses (double umbilical cord blood transplant (dUCBT) and haplo-identical transplants).

The hypothesis is that thiotepa at a dose of 10mg/kg, in combination with melphalan (100mg/m2) and fludarabine (160mg/m2) as a reduced intensity conditioning regimen for alternative donor transplant is safe and effective in patients with hematologic malignancies.

Given that this regimen has been investigated extensively, and the current study proposes to confirm those previous observations with a small modification (melphalan dose reduction due to previous mucositis rates with higher doses), this will be a phase II study designed to measure disease-free-survival.

Detailed description: Primary Objective:

To assess the effectiveness of Thiotepa, Fludarabine, and Melphalan in alternative donor transplants as measured by leukemia free survival.

Secondary Objective:

To assess the 1- year OS, Relapse, TRM, aGVHD and cGVHD rates and the rates of neutrophil and platelet engraftment.

Study Design This is a Phase II study of Thiotepa, Fludarabine, and Melphalan in alternative donor transplants.

Subjects will be assessed for safety and tolerability (including adverse events, serious adverse events, and clinical/laboratory assessments) using a continuous monitoring approach. Subjects will be followed for up to 1 year or until progression of disease, relapse, or death.

Eligibility criteria: Inclusion Criteria:

* Patients with the following hematologic malignancies:

  * Acute myelogenous leukemia (AML): High-risk AML including:

    * Antecedent hematological disease (e.g., myelodysplasia (MDS))
    * Treatment-related leukemia
    * Complete Remission (CR1) with poor-risk cytogenetics or molecular markers (e.g. Flt 3 mutation, 11q23, del 5, del 7, complex cytogenetics)
    * Second complete remission (CR2) or third complete remission (CR3)
    * Induction failure or 1st relapse with ≤ 10% blasts in the marrow
  * Acute lymphoblastic leukemia (ALL)

    * High-risk CR1 including:

      * Poor-risk cytogenetics (e.g., Philadelphia chromosome t(9;22)or 11q23 rearrangements)
      * Presence of minimal disease by flow cytometry after 2 or more cycles of chemotherapy
    * No CR within 4 weeks of initial treatment
    * Induction failure with ≤ 10% blasts in the marrow
    * CR2 or CR3
  * Myelodysplastic syndromes (MDS), Intermediate, High or Very High Risk by the revised international prognostic scoring system (IPSS-R)
  * Mixed Phenotypic Leukemia / Biphenotypic Leukemiain CR
  * Chronic Myelogenous Leukemia (CML) in second chronic phase after accelerated or blast crisis.
  * Myelofibrosis (MF):

    * Intermediate-2 or high risk by Dynamic International Prognostic Scoring System (DIPSS-plus) or
    * Monosomal karyotype or
    * Presence of inv(3)/i(17q) abnormalities or
    * Other unfavorable karyotype OR leukocytes ≥40 × 10(9) /L and
    * Circulating blasts ≤ 9%
  * Relapsed or Refractory Lymphoid Malignancies (including non-Hodgkin Lymphoma, Hodgkin Lymphoma and Chronic Lymphocytic Leukemia) meeting the following criteria:

    * Disease status: Stable Disease, Partial Remission or 2nd and 3rd Complete Remission. OR
    * Have relapsed after autologous transplant or who have failed to collect for an autologous transplant.
* Eastern Cooperative Oncology Group (ECOG) Performance status ≤ 2
* Patients without a matched related or unrelated donor
* Patient with either one or both:

  * Two 5/8 human leukocyte antigen (HLA) high resolution matched umbilical cord blood (UCB) grafts with a cell dose of 2.0x10\^7 total number of nucleated cells per kilogram (TNC/kg) each, or
  * A related haplo-identical donor
* Concurrent Therapy for Extramedullary Leukemia or central nervous system (CNS) Lymphoma: Concurrent therapy or prophylaxis for testicular leukemia, CNS leukemia, and CNS lymphoma including standard intrathecal chemotherapy and/or radiation therapy will be allowed as clinically indicated. Such treatment may continue until the planned course is completed. Subjects must be in CNS remission at the time of protocol enrollment if there is a history of CNS involvement. Maintenance therapy after transplant is allowed.
* Subjects must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

* Patients with inadequate Organ Function as defined by:

  * Creatinine clearance \<50ml/min
  * Bilirubin \> twice institutional upper limit of normal
  * aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) ≥ three times institutional upper limit of normal
  * Alanine aminotransferase (ALT) serum glutamic pyruvic transaminase (SGPT) ≥ three times institutional upper limit of normal
  * Pulmonary function: diffusing capacity of the lung for carbon monoxide corrected for hemoglobin (DLCOc) \< 60% normal
  * Cardiac: left ventricular ejection fraction \< 50%
  * Karnofsky Performance Statue (KPS) \< 80
* Patients with uncontrolled inter-current illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
* Pregnant or breastfeeding women are excluded from this study because chemotherapy involved with Reduced Intensity Conditioning (RIC) have the significant potential for teratogenic or abortifacient effects.
* Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the subject; or interfere with interpretation of study data.
* Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds
* Presence of donor-specific antibodies against chosen graft source.

Primary outcomes:
measure: Percentage of patients with leukemia free survival
timeFrame: Up to 1 year after transplant
Secondary outcomes:
measure: Average overall survival
timeFrame: Up to 1 year after transplant
measure: Relapse incidence
timeFrame: Up to 1 year after transplant
measure: Treatment Related Mortality
timeFrame: Up to 1 year after transplant
measure: Incidence of acute GVHD
timeFrame: Up to 1 year after transplant
measure: Incidence of chronic GVHD
timeFrame: Up to 1 year after transplant
measure: Rate of neutrophil engraftment
timeFrame: Up to 1 year after transplant
measure: Rate of platelet engraftment
timeFrame: Up to 1 year after transplant
Other outcomes:
Locations:
city: Cleveland
country: United States
facility: University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
state: Ohio
Study officials:
affiliation: Case Comprehensive Cancer Center
name: Leland Metheny, MD
role: PRINCIPAL_INVESTIGATOR
References: